Home
About Us
Hycells Profile
Corporate Culture
Honors Qualifications
Contact Us
Sample Service
Immune Cells
Hepatocytes
Stem Cells
Featured Products
Cultivation Products
Testing Products
Other Products And Instruments
Technical Service Platform
Specialized Sample Services
Conventional Drug Efficacy Evaluation
Granulocyte Function Experiment
Whole Blood/Serum Test
Drug Immunogenicity Testing
Drug Blood Toxicity Testing
Technology Center
Frequently Asked Questions
Operational Skills
Training Salon
Blog
Company News
Industry Trends
Laws Regulations
Language
中文版
English
All Categories >
05
2026-01
Hycells Recruitment | Continuous Exploration and Innovation
Hycells Bio is a biotechnology company specializing in primary cell technologies and innovative solutions. Headquartered in Wuxi, the company operates dual hubs in Wuxi and Shanghai: the Wuxi center focuses on product R&D, manufacturing, and commercialization, while the Shanghai center concentrates on primary cell preparation and technical services. The company is committed to providing domestically developed, proprietary tools and technologies for biopharmaceutical R&D and manufacturing. Leveraging its independent technology platform, it has launched a comprehensive portfolio of products, including primary immune cells, stem cells, primary animal cells, flow cytometry antibodies for CAR-positive rate detection, immune cell expansion culture media, stem cell expansion and differentiation media, cryopreservation solutions, and cell culture additives. In addition, drawing on its rich resources and technological strengths in primary cells, the company has expanded into in vitro efficacy evaluation, drug immunogenicity assessment, and in vitro blood toxicity testing services. Several of its products and services have already broken the long-standing monopoly held by foreign suppliers, achieving domestic substitution and even surpassing their performance.
2026-01-05
09
2025-12
Integrated Cultivation and Empowerment for Healthy Aging | Professor Zhang Xianzheng of Wuhan University Publishes in Advanced Materials, Revealing a Novel Strategy for Reprogramming Aging (IF: 26.8)
Recently, Professor Xianzheng Zhang’s team from the School of Chemistry and Molecular Sciences at Wuhan University published a research paper titled “Senescence Reprogramming Unleashes Tumor Immune Surveillance via Coordinated Gene Modulation” in the top materials science journal Advanced Materials. This study proposes an innovative cancer therapy strategy that achieves tumor-specific senescence reprogramming by jointly regulating two key targets—P16INK4a and PD-L1—thereby activating the immune system to combat tumors.
2025-12-09
14
2025-11
HiXpan® Cell Culture Additive | Meets Drug Regulatory Submission Requirements, Setting a New Benchmark for Industry Compliance
Cell culture supplements are chemically defined or animal-free additives used in cell culture to replace traditional animal sera, such as fetal bovine serum, with the aim of reducing batch-to-batch variability, minimizing contamination risks, and enhancing experimental reproducibility. Their composition typically includes growth factors, carrier proteins, trace elements, and other components, making them suitable for applications in vaccine production, biopharmaceuticals, regenerative medicine, and other fields.
2025-11-14
06
One-Stop Comprehensive Solution for In Vitro Immunogenicity Assessment
With the rapid advancement of biotechnology-based therapeutics—including therapeutic proteins, monoclonal antibodies, and cell and gene therapy products—immunogenicity assessment has become an indispensable and critical component of drug development and clinical safety monitoring. Immunogenicity refers to the phenomenon in which the body recognizes therapeutic protein drugs as foreign antigens, thereby triggering an immune response. Unnecessary or unexpected immune reactions can severely compromise a drug’s safety and efficacy.
2025-11-06
04
Application Showcase | Hycells One-Stop Comprehensive NK Cell Solution
Shanghai Hycells Biotechnology Co., Ltd. is a high-tech enterprise specializing in research on primary immune cells and stem cells. The company has established an integrated technology platform covering both immune cells and mesenchymal stem cells (MSCs), dedicated to providing customers with end-to-end cell-based solutions.
2025-11-04
Call for Papers | Application Process Now Open for 2025 SCI Paper Awards
On the journey of exploring life sciences, every breakthrough is worth celebrating, and every bit of support is worthy of gratitude. Hycells has consistently stood by your side, providing high-quality sample services, technical support, and specialized products to empower your research and development efforts. To express our heartfelt appreciation for the trust and support of both new and longstanding customers, Hycells is proudly launching a paper submission reward program—offering exclusive rewards as a token of our gratitude and paying tribute to every researcher!